ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA grants ODD for AstraZeneca’s Fasenra to treat EGPA
November 29, 2018The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for AstraZeneca’s Fasenra (benralizumab) to treat eosinophilic granulomatosis with polyangiitis (EGPA)..... -
FDA Approves First Drug for Eosinophilic Granulomatosis with Polyangiitis
December 14, 2017FDA expanded the approved use of Nucala to treat adult patients with eosinophilic granulomatosis with polyangiitis , a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body
Pharma Sources Insight January 2025
